AAPL   322.32 (-0.86%)
MSFT   182.92 (-1.32%)
FB   226.29 (-1.68%)
GOOGL   1,414.30 (-1.73%)
AMZN   2,460.60 (-0.72%)
NVDA   350.66 (-0.03%)
CGC   16.63 (+0.36%)
BABA   218.04 (-0.26%)
MU   51.22 (+4.70%)
GE   7.74 (+5.16%)
TSLA   864.38 (-2.10%)
AMD   52.63 (-0.19%)
T   31.80 (+0.92%)
ACB   14.23 (-0.49%)
F   6.57 (+6.14%)
GILD   77.54 (+4.22%)
DIS   123.69 (+1.24%)
NFLX   414.33 (-1.81%)
BAC   26.78 (+3.04%)
BA   184.30 (+6.43%)
AAPL   322.32 (-0.86%)
MSFT   182.92 (-1.32%)
FB   226.29 (-1.68%)
GOOGL   1,414.30 (-1.73%)
AMZN   2,460.60 (-0.72%)
NVDA   350.66 (-0.03%)
CGC   16.63 (+0.36%)
BABA   218.04 (-0.26%)
MU   51.22 (+4.70%)
GE   7.74 (+5.16%)
TSLA   864.38 (-2.10%)
AMD   52.63 (-0.19%)
T   31.80 (+0.92%)
ACB   14.23 (-0.49%)
F   6.57 (+6.14%)
GILD   77.54 (+4.22%)
DIS   123.69 (+1.24%)
NFLX   414.33 (-1.81%)
BAC   26.78 (+3.04%)
BA   184.30 (+6.43%)
AAPL   322.32 (-0.86%)
MSFT   182.92 (-1.32%)
FB   226.29 (-1.68%)
GOOGL   1,414.30 (-1.73%)
AMZN   2,460.60 (-0.72%)
NVDA   350.66 (-0.03%)
CGC   16.63 (+0.36%)
BABA   218.04 (-0.26%)
MU   51.22 (+4.70%)
GE   7.74 (+5.16%)
TSLA   864.38 (-2.10%)
AMD   52.63 (-0.19%)
T   31.80 (+0.92%)
ACB   14.23 (-0.49%)
F   6.57 (+6.14%)
GILD   77.54 (+4.22%)
DIS   123.69 (+1.24%)
NFLX   414.33 (-1.81%)
BAC   26.78 (+3.04%)
BA   184.30 (+6.43%)
AAPL   322.32 (-0.86%)
MSFT   182.92 (-1.32%)
FB   226.29 (-1.68%)
GOOGL   1,414.30 (-1.73%)
AMZN   2,460.60 (-0.72%)
NVDA   350.66 (-0.03%)
CGC   16.63 (+0.36%)
BABA   218.04 (-0.26%)
MU   51.22 (+4.70%)
GE   7.74 (+5.16%)
TSLA   864.38 (-2.10%)
AMD   52.63 (-0.19%)
T   31.80 (+0.92%)
ACB   14.23 (-0.49%)
F   6.57 (+6.14%)
GILD   77.54 (+4.22%)
DIS   123.69 (+1.24%)
NFLX   414.33 (-1.81%)
BAC   26.78 (+3.04%)
BA   184.30 (+6.43%)
Log in

NASDAQ:TGTXTG Therapeutics Stock Price, Forecast & News

$17.59
-0.29 (-1.62 %)
(As of 06/4/2020 04:00 PM ET)
Add
Compare
Today's Range
$17.30
Now: $17.59
$18.21
50-Day Range
$9.94
MA: $16.33
$21.84
52-Week Range
$4.95
Now: $17.59
$22.28
Volume1.40 million shs
Average Volume2.26 million shs
Market Capitalization$1.94 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.45
TG Therapeutics, Inc., a biopharmaceutical company, engages in developing and delivering medicines for patients with chronic lymphocytic leukemia (CLL), non-Hodgkin's Lymphoma (NHL), and Multiple Sclerosis (MS). It develops a robust B-cell directed research and development platform for identification of key B-cell pathways of interest and rapid clinical testing. The company has five B-cell targeted drug candidates in clinical development, with the lead two therapies, such as Ublituximab and Umbralisib in pivotal trials for CLL, NHL, and MS. Its Ublituximab is a novel anti-CD20 monoclonal antibody that has been glycoengineered for enhanced potency over first generation antibodies; and Umbralisib is an oral, once daily inhibitor of PI3K delta. The company also develops TG-1501, an anti-PD-L1 monoclonal antibody; TG-1701, an oral Bruton's Tyrosine Kinase; and TG-1801, an anti-CD47/CD19 bispecific antibody. TG Therapeutics, Inc. has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A; Checkpoint Therapeutics, Inc.; Jiangsu Hengrui Medicine Co.; Novimmune SA; Ligand Pharmaceuticals Incorporated; and Jubilant Biosys. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.
Read More
TG Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 3.3Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.69 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TGTX
CUSIPN/A
Phone212-554-4484

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$150,000.00
Price / Sales12,919.03
Book Value$0.39 per share

Profitability

Net Income$-172,870,000.00
Net Margins-124,230.27%

Miscellaneous

Employees105
Market Cap$1.94 billion
Next Earnings Date8/14/2020 (Estimated)
OptionableOptionable

Receive TGTX News and Ratings via Email

Sign-up to receive the latest news and ratings for TGTX and its competitors with MarketBeat's FREE daily newsletter.

TG Therapeutics (NASDAQ:TGTX) Frequently Asked Questions

How has TG Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

TG Therapeutics' stock was trading at $10.01 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, TGTX stock has increased by 75.7% and is now trading at $17.59. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of TG Therapeutics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TG Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for TG Therapeutics.

When is TG Therapeutics' next earnings date?

TG Therapeutics is scheduled to release its next quarterly earnings announcement on Friday, August 14th 2020. View our earnings forecast for TG Therapeutics.

How were TG Therapeutics' earnings last quarter?

TG Therapeutics Inc (NASDAQ:TGTX) announced its quarterly earnings results on Monday, May, 11th. The biopharmaceutical company reported ($0.48) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.36) by $0.12. The biopharmaceutical company had revenue of $0.04 million for the quarter, compared to analyst estimates of $0.04 million. TG Therapeutics had a negative return on equity of 2,937.74% and a negative net margin of 124,230.27%. View TG Therapeutics' earnings history.

What price target have analysts set for TGTX?

3 brokers have issued twelve-month price targets for TG Therapeutics' stock. Their forecasts range from $32.00 to $37.00. On average, they expect TG Therapeutics' stock price to reach $34.67 in the next year. This suggests a possible upside of 97.1% from the stock's current price. View analysts' price targets for TG Therapeutics.

Has TG Therapeutics been receiving favorable news coverage?

Media stories about TGTX stock have been trending neutral this week, according to InfoTrie. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. TG Therapeutics earned a daily sentiment score of 0.4 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the next few days. View the latest news aboutTG Therapeutics.

Who are some of TG Therapeutics' key competitors?

What other stocks do shareholders of TG Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TG Therapeutics investors own include Novavax (NVAX), AK Steel (AKS), Micron Technology (MU), Amarin (AMRN), UrtheCast (UR), Gilead Sciences (GILD), BioDelivery Sciences International (BDSI), AcelRx Pharmaceuticals (ACRX), Cara Therapeutics (CARA) and Synergy Pharmaceuticals (SGYP).

Who are TG Therapeutics' key executives?

TG Therapeutics' management team includes the following people:
  • Mr. Michael S. Weiss, Exec. Chairman, CEO & Pres (Age 53)
  • Mr. Sean A. Power CPA, CFO, Corp. Sec. & Treasurer (Age 37)
  • Jenna Bosco, VP of Investor Relations & Sr. VP of Corp. Communications
  • Mr. Adam Waldman, Chief Commercial Officer

What is TG Therapeutics' stock symbol?

TG Therapeutics trades on the NASDAQ under the ticker symbol "TGTX."

Who are TG Therapeutics' major shareholders?

TG Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include RA Capital Management L.P. (9.43%), BlackRock Inc. (5.58%), State Street Corp (3.17%), Geode Capital Management LLC (1.22%), Lord Abbett & CO. LLC (0.86%) and Nuveen Asset Management LLC (0.57%). Company insiders that own TG Therapeutics stock include Michael S Weiss, Sean A Power and William James Kennedy. View institutional ownership trends for TG Therapeutics.

Which major investors are selling TG Therapeutics stock?

TGTX stock was sold by a variety of institutional investors in the last quarter, including Sofinnova Investments Inc., Rafferty Asset Management LLC, JPMorgan Chase & Co., Raymond James & Associates, Wells Fargo & Company MN, Frontier Wealth Management LLC, HighTower Advisors LLC, and Raymond James Financial Services Advisors Inc.. View insider buying and selling activity for TG Therapeutics.

Which major investors are buying TG Therapeutics stock?

TGTX stock was purchased by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, RA Capital Management L.P., Nuveen Asset Management LLC, Geode Capital Management LLC, Ghost Tree Capital LLC, Federated Hermes Inc., State Street Corp, and BlackRock Inc.. View insider buying and selling activity for TG Therapeutics.

How do I buy shares of TG Therapeutics?

Shares of TGTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is TG Therapeutics' stock price today?

One share of TGTX stock can currently be purchased for approximately $17.59.

How big of a company is TG Therapeutics?

TG Therapeutics has a market capitalization of $1.94 billion and generates $150,000.00 in revenue each year. The biopharmaceutical company earns $-172,870,000.00 in net income (profit) each year or ($1.83) on an earnings per share basis. TG Therapeutics employs 105 workers across the globe.

What is TG Therapeutics' official website?

The official website for TG Therapeutics is www.tgtherapeutics.com.

How can I contact TG Therapeutics?

TG Therapeutics' mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The biopharmaceutical company can be reached via phone at 212-554-4484 or via email at [email protected]

This page was last updated on 6/4/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.